Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has made a 119.38% comeback from a 12-month low price of $1.29. It was seen 5.2% higher, changing the price to $2.83, when the closing bell rang on 3/11/2019. At a recent session, the prices were hovering between $2.67 and $2.855. This company shares are 94.35% off its target price of $5.5 and the current market capitalization stands at $392.35M. The recent change has given its price a 27.6% lead over SMA 50 and -34.79% deficit over its 52-week high. The stock witnessed 32.24% gains, -9.58% declines and -16.27% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ACHN’s volatility during a week at 6.7% and during a month it has been found around 5.95%.Achillion Pharmaceuticals, Inc. (ACHN) Top Holders
Institutional investors currently hold around $278 million or 78.6% in ACHN stock. Look at its top three institutional owners: Rtw Investments, Lp owns $36.99 million in Achillion Pharmaceuticals, Inc., which represents roughly 9.43% of the company’s market cap and approximately 13.3% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 12,101,177 shares of the stock are valued at $32.55 million. The third largest holder is Vanguard Group Inc, which currently holds $23.18 million worth of this stock and that ownership represents nearly 5.91% of its market capitalization.
At the end of December reporting period, 50 institutional holders increased their position in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by some 18,032,887 shares, 69 decreased positions by 24,365,356 and 29 held positions by 60,780,480. That puts total institutional holdings at 103,178,723 shares, according to SEC filings. The stock grabbed 11 new institutional investments totaling 1,913,747 shares while 27 institutional investors sold out their entire positions totaling 13,084,994 shares.Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Insider Trades
Multiple company employees have indulged in significant insider trading. Achillion Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that 10% Owner Johnson & Johnson has sold 18,367,346 shares of Achillion Pharmaceuticals, Inc. (ACHN) in the trading session dated Nov. 20, 2017. These shares are worth $50,510,202 and were traded at $2.75 each. The SEC filing shows that Fisherman Jason S performed a purchase of 10,000 shares. The Director added these shares by way of transaction on Dec. 22, 2016. The company’s shares were assimilated at $3.96 per share worth to an investment of some $39,600 to the account of Fisherman Jason S.
CFO, Fenton Mary Kay, purchased 2,500 common shares of Achillion Pharmaceuticals, Inc. (ACHN) in the open market. In a transaction dated Dec. 05, 2016, the shares were bought at an average price of $4.11, giving away a sum of $10,275. After this purchase, 2,500 common shares of ACHN are directly owned by the insider, with total stake valued at $7,075.
In the transaction dated Dec. 02, 2016, a great number of shares acquired came courtesy the Chief Commercial Officer; Truitt Joseph added a total of 3,500 shares at an average price of $4.06, amounting to approximately $14,210. The insider now directly owns 3,500 shares worth $9,905.Achillion Pharmaceuticals, Inc. (ACHN) Analyst Guide
Several analysts have released their opinion on Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), with 2 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.75 average brokerage recommendation [T1].